Two Sigma Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Two Sigma Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,900	Closed	-$675K	–	2060
2020 Q3	$675K	Buy	+5,900	New	+$636K	0.01%	486
2020 Q2	–	Sell	-6,400	Closed	-$575K	–	1861
2020 Q1	$575K	Sell	6,400 -56,600	-90%	-$5.55M	0.01%	567
2019 Q4	$6.81M	Buy	63,000 +55,500	+740%	+$5.94M	0.05%	321
2019 Q3	$735K	Sell	7,500 -8,600	-53%	-$969K	0.01%	1016
2019 Q2	$2.11M	Buy	16,100 +6,800	+73%	+$876K	0.02%	448
2019 Q1	$1.26M	Sell	9,300 -19,600	-68%	-$2.44M	0.01%	477
2018 Q4	$2.81M	Sell	28,900 -33,500	-54%	-$3.96M	0.03%	266
2018 Q3	$8.67M	Buy	62,400 +23,300	+60%	+$2.92M	0.06%	241
2018 Q2	$4.85M	Sell	39,100 -40,100	-51%	-$4.69M	0.02%	504
2018 Q1	$8.83M	Buy	+79,200	New	+$9.47M	0.05%	316

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's ALXN Position: Q1 2021 in Review

Two Sigma Securities sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,599 shares — an estimated $250K sold.

Two Sigma Securities first reported a position in ALXN in Q4 2015 and held it in 9 quarters. The position peaked at $1.95M in Q2 2018. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Two Sigma Securities reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Two Sigma Securities sold 1,599 Alexion Pharmaceuticals shares in Q1 2021, an estimated $250K.
Two Sigma Securities first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Two Sigma Securities's Alexion Pharmaceuticals position peaked at $1.95M in Q2 2018.
753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Two Sigma Securities's 13F filing for Q1 2021, filed 17 May 2021.